Quoin Pharmaceuticals, Ltd. - 8-K Filing
Quoin Pharmaceuticals reported first-quarter 2026 financial results with a net loss of $5 million and $14 million in cash, cash equivalents, and marketable securities as of March 31, 2026. The company highlighted regulatory progress for QRX003 in Netherton Syndrome, including FDA Fast Track Designation, a constructive Type C meeting suggesting a single Phase 3 trial may suffice for U.S. approval, and Orphan Drug and Fast Track designations in Japan. Quoin also filed for Breakthrough Medicine Designation in Saudi Arabia and plans to submit an IND for QRX009 by Q3 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $QNRX